Ginkgo Bioworks Holdings, Inc.
corporate_fare Company Profile
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for DNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for DNA spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Ginkgo Bioworks Q2 Revenue Halves to $20M, Cash Runway Tightens as $47M Gets Locked Up
- Ginkgo Bioworks Reports 49% Revenue Decline, Q1 Loss; $47M Cash Restricted Post-Quarter
- Ginkgo Bioworks Q1 Revenue Plummets 49% to $19.5M Amid Continued Losses
- Ginkgo Bioworks Completes Strategic Biosecurity Segment Sale, Provides Pro Forma Financials
- Ginkgo Bioworks Finalizes Divestiture of Biosecurity Segment, Retains 20% Equity Stake
Financial Snapshot
Short Interest & Short Volume
7.20 days to coverFINRA reported short interest of 7,166,128 shares in DNA as of the September 15, 2026 settlement, a 4.4% increase from the prior period — about 7.2 days to cover at its recent average daily volume. On October 2, 2026, 62.9% of DNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.